Avalo Therapeutics regains Nasdaq compliance on market value standard; matter closed

Avalo Therapeutics, Inc.

Received written confirmation from Nasdaq on Sept 3, 2024 that market value exceeded $35M for 10 consecutive trading days.
Regains compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities Standard).
Previously received notice on May 20, 2024 for non-compliance with Stockholders' Equity Requirement.
Compliance regained resolves the deficiency; no further Nasdaq action required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.